![]() |
|
|
Vol. 302, Issue 1, 264-273, July 2002
Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard
Medical School, Belmont, Massachusetts
It has been suggested that heroin and morphine may act on different
opioid receptor populations in rodents. In support of this hypothesis,
the opioid antagonist 3-methoxynaltrexone was reported to be more
potent as an antagonist of the antinociceptive effects of heroin than
of morphine in mice and rats. To assess the generality of this finding
across species and experimental endpoints, the present study compared
the potencies of naltrexone and 3-methoxynaltrexone as antagonists of
heroin and morphine in two behavioral assays in rhesus monkeys. In the
thermal nociception study, tail-withdrawal latencies were measured from
water heated to 50°C. In the heroin discrimination study, monkeys
were trained to discriminate 0.1 mg/kg heroin from saline in a two-key,
food-reinforced drug discrimination procedure, and percentage of
heroin-appropriate responding and response rates were measured. Both
heroin and morphine produced dose-dependent antinociception, increases
in percentage of heroin-appropriate responding, and decreases in
response rates. Heroin was approximately 20-fold more potent than
morphine. Naltrexone (0.032-0.1 mg/kg) was equipotent in antagonizing
all effects of heroin and morphine (pA2
values = 7.90-8.22). 3-Methoxynaltrexone (0.1-3.2 mg/kg) was
also equipotent in antagonizing the antinociceptive, discriminative
stimulus, and rate-suppressant effects of heroin and morphine; however,
3-methoxynaltrexone was approximately 100-fold less potent than
naltrexone (pA2/pKB
values = 5.96-6.36). These results suggest that heroin and
morphine act on pharmacologically similar populations of opioid
receptors in rhesus monkeys, and also indicate that 3-methoxynaltrexone
does not differentially antagonize the effects of heroin and morphine
in rhesus monkeys.
This article has been cited by other articles:
![]() |
G. P. Do Carmo, R. Polt, E. J. Bilsky, K. C. Rice, and S. S. Negus Behavioral Pharmacology of the {micro}/{delta} Opioid Glycopeptide MMP2200 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 939 - 948. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Hawkinson, B. G. Szoke, A. W. Garofalo, D. S. Hom, H. Zhang, M. Dreyer, J. Y. Fukuda, L. Chen, B. Samant, S. Simmonds, et al. Pharmacological, Pharmacokinetic, and Primate Analgesic Efficacy Profile of the Novel Bradykinin B1 Receptor Antagonist ELN441958 J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 619 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stevenson, J. E. Folk, K. C. Rice, and S. S. Negus Interactions between {delta} and {micro} Opioid Agonists in Assays of Schedule-Controlled Responding, Thermal Nociception, Drug Self-Administration, and Drug versus Food Choice in Rhesus Monkeys: Studies with SNC80 [(+)-4-[({alpha}R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and Heroin J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 221 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Platt, J. K. Rowlett, S. Izenwasser, and R. D. Spealman Opioid Partial Agonist Effects of 3-O-Methylnaltrexone in Rhesus Monkeys J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1030 - 1039. [Abstract] [Full Text] [PDF] |
||||